In Q4 2010 Redbiotec demonstrated a specific immune response to its chimeric human papilloma virus-like particles (VLPs) in mice. Over the last 2 years Redbiotec successfully produced over 20 monomeric and chimeric human papilloma virus VLPs as potential vaccine candidates.
Redbiotec – Successful in vivo results for HPV program
This entry was posted in Portfolio and tagged human papilloma virus, Redbiotec, vaccines.
Bookmark the permalink. Follow any comments here with the RSS feed for this post.
Post a comment or leave a trackback: Trackback URL.
Bookmark the permalink. Follow any comments here with the RSS feed for this post.
Post a comment or leave a trackback: Trackback URL.
